284 related articles for article (PubMed ID: 31105051)
1. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.
Fawzy A; Sweify KM; El-Fayoumy HM; Nofal N
J Egypt Natl Canc Inst; 2016 Dec; 28(4):235-242. PubMed ID: 27634416
[TBL] [Abstract][Full Text] [Related]
3. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
5. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience.
Li M; Jia Y; Xu J; Cheng X; Xu C
Ann Hematol; 2017 Aug; 96(8):1343-1351. PubMed ID: 28623396
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
[TBL] [Abstract][Full Text] [Related]
10. Circulating Plasma Tumor DNA.
Parsons HA; Beaver JA; Park BH
Adv Exp Med Biol; 2016; 882():259-76. PubMed ID: 26987539
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
12. Reduced Serum Circulation of Cell-Free DNA Following Chemotherapy in Breast Cancer Patients.
Adusei E; Ahenkorah J; Adu-Aryee NA; Adutwum-Ofosu KK; Tagoe EA; Koney NK; Nkansah E; Aryee NA; Blay RM; Hottor BA; Clegg-Lamptey JN; Arko-Boham B
Med Sci (Basel); 2021 May; 9(2):. PubMed ID: 34070520
[TBL] [Abstract][Full Text] [Related]
13. Prediction of breast tumor progression by integrity of free circulating DNA in serum.
Umetani N; Giuliano AE; Hiramatsu SH; Amersi F; Nakagawa T; Martino S; Hoon DS
J Clin Oncol; 2006 Sep; 24(26):4270-6. PubMed ID: 16963729
[TBL] [Abstract][Full Text] [Related]
14. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
15. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.
Kamel AM; Teama S; Fawzy A; El Deftar M
Tumour Biol; 2016 Jun; 37(6):7565-72. PubMed ID: 26684805
[TBL] [Abstract][Full Text] [Related]
16. The role of circulating cell-free DNA and its integrity as a biomarker for diagnosis of breast cancer using ALU (247/115) bP sequences.
Abd El Hafeez HA; Abd El Rahman MZ; Kamel TM; Rezk KM; Mohamed FM; Abdel-Hameed ZA
Egypt J Immunol; 2023 Jul; 30(3):44-55. PubMed ID: 37439529
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Iran Biomed J; 2018 Sep; 22(5):331-7. PubMed ID: 29475366
[TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients.
Saucedo-Sariñana AM; Lugo-Escalante CR; Barros-Núñez P; Marín-Contreras ME; Pineda-Razo TD; Mariscal-Ramírez I; Gallegos-Arreola MP; Rosales-Reynoso MA
Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):1-8. PubMed ID: 36227685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
